What does the LDL Cholesterol (Low-Density Lipoprotein Cholesterol) test measure?

Why is LDL Cholesterol (Low-Density Lipoprotein Cholesterol) measured?

LDL-C is the most extensively validated modifiable ASCVD risk factor and the primary pharmacological target of lipid-lowering therapy across all major cardiovascular guidelines. The causal relationship between LDL-C and ASCVD is established through Mendelian randomisation studies in familial hypercholesterolaemia and hypocholesterolaemia populations, statin and PCSK9 inhibitor trial data, and epidemiological cohort analysis — with each 1 mmol/L (approximately 39 mg/dL) reduction in LDL-C associated with approximately 22% relative risk reduction in major adverse cardiovascular events (MACE). In the full lipid panel, LDL-C drives the key clinical decision: whether to initiate lipid-lowering pharmacotherapy, at what intensity, and to what treatment target — with risk-stratified targets ranging from <100 mg/dL in primary prevention with risk factors to <55 mg/dL in very-high-risk established ASCVD patients per 2019 ESC/EAS guidelines.

Reference ranges

Standard reference

Optimal: <100 mg/dL (<2.59 mmol/L); Near optimal: 100–129 mg/dL; Borderline high: 130–159 mg/dL; High: 160–189 mg/dL; Very high: ≥190 mg/dL (≥4.91 mmol/L) # REVIEWER FLAG: Confirm LabCorp LDL-C reporting format — confirm whether LabCorp uses the Friedewald equation (TC − HDL − [TG ÷ 5]) or the Martin-Hopkins equation (validated at lower LDL-C and higher TG concentrations) as the default calculation for this panel, and whether direct LDL-C measurement is automatically applied when triglycerides exceed the Friedewald reliability threshold (typically 400 mg/dL). Also confirm whether LabCorp applies NCEP ATP III categorical labelling or provides a numerical value with practitioner-applied risk stratification.

Functional medicine optimal

<70 mg/dL (preventive cardiology optimal for patients with any cardiovascular risk factors); <55 mg/dL (very-high-risk and established ASCVD per 2019 ESC/EAS); <100 mg/dL (ACC/AHA 2018 lower boundary for pharmacotherapy consideration in intermediate-risk patients). # REVIEWER FLAG: LDL-C treatment targets are risk-stratified and differ materially between ACC/AHA 2018 and ESC/EAS 2019 frameworks — reviewer to confirm which guideline framework is most appropriate for this platform's practitioner audience and whether risk-stratified target tiers should be documented.

Units

mg/dL, mmol/L

Reference ranges vary by laboratory and assay platform. Interpret in context of the issuing laboratory's stated range.